{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:43Z","timestamp":1787628103541,"version":"build-2736575974"},"reference-count":37,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,8,24]]},"DOI":"10.1080\/10428194.2025.2506498","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:09:37Z","timestamp":1749463777000},"page":"1850-1862","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed\/refractory follicular lymphoma"],"prefix":"10.1080","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3004-8438","authenticated-orcid":false,"given":"Meng-Hsuan","family":"Lin","sequence":"first","affiliation":[{"name":"School of Public Health, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"City of Hope","place":["Pasadena, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Sano","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon A.","family":"Carty","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria R.","family":"Nachar","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hutton","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-4448","authenticated-orcid":false,"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_3_3_3_1","unstructured":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label multicentre randomised phase 3 non-inferiority trial. PubMed. [accessed April 8 2024]. Available from: https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.lib.umich.edu\/23433739\/."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_3_3_9_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. FDA. [published online June 11 2021; accessed March 3 2024]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma"},{"key":"e_1_3_3_10_1","unstructured":"U.S. Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma. FDA. [published online June 23 2022; accessed March 3 2024]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma"},{"key":"e_1_3_3_11_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. FDA. [published online January 19 2023; accessed March 3 2024]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_3_16_1","unstructured":"Centers for Medicare & Medicaid Services. 2023 ASP pricing files. [accessed March 24 2023]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"e_1_3_3_17_1","unstructured":"Micromedex Red Book. [accessed March 24 2023]. Available from: https:\/\/www-micromedexsolutions-com.proxy.lib.umich.edu\/micromedex2\/librarian\/CS\/87EFD9\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/5A7A30\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=LUNSUMIO&searchType=redbookProductName&searchTermId=53919&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Elunsumio."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194627"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567"},{"key":"e_1_3_3_22_1","unstructured":"Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule (CY 2023 Q2 release). [accessed March 24 2023]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs"},{"key":"e_1_3_3_23_1","unstructured":"Centers for Medicare & Medicaid Services. Hospital outpatient PPS: Addendum A and Addendum B updates (Jan 2023 Addendum B). [accessed March 24 2023]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/hospital-outpatient\/addendum-a-b-updates"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008097"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"e_1_3_3_26_1","unstructured":"U.S. Bureau of Economic Analysis. Gross domestic product: implicit price deflator. FRED Federal Reserve Bank of St. Louis. 1947. [accessed March 24 2024]. Available from: https:\/\/fred.stlouisfed.org\/series\/GDPDEF"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29372"},{"key":"e_1_3_3_28_1","unstructured":"Overview\u2014Mosunetuzumab for treating relapsed or refractory follicular lymphoma\u2014Guidance. NICE. 2023. [accessed April 16 2024]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA892"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311816"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.008"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17527"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185138"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127452"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00346-7"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05315-1"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.446"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2506498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:06:24Z","timestamp":1759273584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2506498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8,24]]}},"alternative-id":["10.1080\/10428194.2025.2506498"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2506498","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}